Keenova Therapeutics Plc's ability to collect accounts receivable sequentially worsen to 3.12, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Keenova Therapeutics Plc's Accounts Receivable average collection period in the Mar 31 2026 quarter, has increased to 117 days, from 116 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 480 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 3181, from overall ranking in the fourth quarter 2025 at 3594.

What is Receivable Turnover Ratio?
What is Keenova Therapeutics Plc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MNK Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 26 2025) III. Quarter	(Mar 28 2025) I. Quarter	(Sep 27 2024) III. Quarter
Y / Y Receivable Change	-7.88 %	-24.34 %	100.98 %	6.68 %	-10.21 %
Y / Y Revenue Change	-7.42 %	-	61.24 %	-48.36 %	1.67 %
Receivable Turnover Ratio (TTM)	3.12	3.15	4.52	4.89	6
MNK's Total Ranking	# 3181	# 3594	# 2925	#	# 2858
Accounts Receivable average collection period days	117	116	81	75	61
Seq. Receivable Change	18.05 %	-60.54 %	88.2 %	5.06 %	-3.04 %
Seq. Revenue Change	-	-	79.33 %	-16.87 %	-1.73 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 155
Healthcare Sector	# 481
Overall Market	# 3181

Receivable Turnover Ratio Statistics
High	Average	Low
6	5.14	3.12
(Sep 27 2024)		(Mar 31 2026)

MNK Company Profile • Back to MNK Efficiency Comparisons • Compare MNK Receivables Turnover Ratio to its Competitors

Financial Statements
Keenova Therapeutics Plc's Accounts Receivable	$ 353 Millions	Visit MNK's Balance sheet
Keenova Therapeutics Plc's Sales TTM	$ 1,413 Millions	Visit MNK's Income Statement
Sources of MNK's Revenues		Visit MNK's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
MNK's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
MNK's Growth Rates	MNK's Roa	MNK's Inventory Turnover Ratio	MNK's Dividend Comparisons
MNK's Profitability Ratios	MNK's Roi	MNK's Asset Turnover Ratio	MNK's Dividend Growth
MNK's Valuation Ratios	MNK's Roe	MNK's Financial Strength Ratios	MNK's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Bioaffinity Technologies Inc	10.79	$ 5.660 Millions	$ 0.525 Millions
Vivos Therapeutics Inc	10.73	$ 19.092 Millions	$ 1.779 Millions
Veracyte Inc	10.68	$ 516.183 Millions	$ 48.353 Millions
Immucell Corporation	10.51	$ 29.035 Millions	$ 2.762 Millions
Kestra Medical Technologies Ltd	10.51	$ 93.819 Millions	$ 8.925 Millions
Lifeloc Technologies Inc	10.41	$ 9.044 Millions	$ 0.869 Millions
Monte Rosa Therapeutics Inc	10.39	$ 42.953 Millions	$ 4.136 Millions
International Stem Cell Corporation	10.23	$ 9.286 Millions	$ 0.908 Millions
Pavmed Inc	10.19	$ 0.107 Millions	$ 0.011 Millions
Viemed Healthcare Inc	10.16	$ 286.565 Millions	$ 28.217 Millions
Addus Homecare Corp	10.14	$ 1,447.070 Millions	$ 142.667 Millions
Utah Medical Products Inc	10.13	$ 36.745 Millions	$ 3.629 Millions
Petvivo Holdings Inc	10.10	$ 0.821 Millions	$ 0.081 Millions
Irhythm Holdings Inc	10.00	$ 787.387 Millions	$ 78.720 Millions
C4 Therapeutics Inc	9.97	$ 34.861 Millions	$ 3.496 Millions
Biodesix Inc	9.94	$ 96.096 Millions	$ 9.665 Millions
Radnet Inc	9.87	$ 2,144.442 Millions	$ 217.223 Millions
Lensar Inc	9.87	$ 57.704 Millions	$ 5.847 Millions
X4 Pharmaceuticals Inc	9.69	$ 9.014 Millions	$ 0.931 Millions
Septerna Inc	9.64	$ 72.255 Millions	$ 7.499 Millions
Encompass Health Corporation	9.63	$ 6,066.400 Millions	$ 629.625 Millions
Biolife Solutions Inc	9.51	$ 99.673 Millions	$ 10.478 Millions
Biofrontera Inc	9.49	$ 42.983 Millions	$ 4.530 Millions
United Therapeutics Corporation	9.47	$ 3,169.800 Millions	$ 334.800 Millions
Tandem Diabetes Care Inc	9.34	$ 1,023.420 Millions	$ 109.550 Millions
Sunshine Biopharma Inc	9.33	$ 35.493 Millions	$ 3.804 Millions
The Oncology Institute Inc	9.30	$ 545.764 Millions	$ 58.671 Millions
The Pennant Group Inc	9.28	$ 1,023.227 Millions	$ 110.305 Millions
Enanta Pharmaceuticals Inc	9.26	$ 69.213 Millions	$ 7.477 Millions
Volitionrx Limited	9.23	$ 2.466 Millions	$ 0.267 Millions

Date modified: 2026-08-29T17:14:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.